Scopus Biopharma Stock Net Asset
| SCPS Stock | USD 0.0006 0.0002 50.00% |
Fundamental analysis of Scopus Biopharma allows traders to better anticipate movements in Scopus Biopharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
Scopus |
Scopus Biopharma OTC Stock Net Asset Analysis
Scopus Biopharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Scopus Biopharma Net Asset | 8.19 M |
Most of Scopus Biopharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scopus Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Scopus Biopharma has a Net Asset of 8.19 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net asset for all United States stocks is notably lower than that of the firm.
Scopus Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in net asset category among its peers.
Scopus Fundamentals
| Return On Equity | -15.6 | |||
| Return On Asset | -4.61 | |||
| Current Valuation | 1.18 M | |||
| Shares Outstanding | 21.09 M | |||
| Shares Owned By Insiders | 50.66 % | |||
| Shares Owned By Institutions | 2.15 % | |||
| Number Of Shares Shorted | 23.77 K | |||
| Price To Book | 2.42 X | |||
| EBITDA | (26.18 M) | |||
| Net Income | (26.95 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 2.54 M | |||
| Debt To Equity | 0.61 % | |||
| Current Ratio | 0.31 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (11.42 M) | |||
| Short Ratio | 0.22 X | |||
| Earnings Per Share | (1.51) X | |||
| Target Price | 12.0 | |||
| Beta | 1.16 | |||
| Market Capitalization | 2.17 M | |||
| Total Asset | 8.19 M | |||
| Z Score | -9.9 | |||
| Net Asset | 8.19 M |
About Scopus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scopus Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scopus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scopus Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scopus OTC Stock Analysis
When running Scopus Biopharma's price analysis, check to measure Scopus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scopus Biopharma is operating at the current time. Most of Scopus Biopharma's value examination focuses on studying past and present price action to predict the probability of Scopus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scopus Biopharma's price. Additionally, you may evaluate how the addition of Scopus Biopharma to your portfolios can decrease your overall portfolio volatility.